Key result
Phytolacca berry lacks clinical trial evidence for lipid lowering despite preliminary animal data.
Why the study?
Phytolacca berry has attracted interest for its proposed effects on lipid metabolism and body weight in dyslipidemia, but evidence is limited to preliminary animal studies and cannot establish clinical efficacy in humans.
Does Phytolacca berry improve lipid profile parameters in individuals with dyslipidemia?
Does Phytolacca berry improve lipid profile parameters in individuals with dyslipidemia?
This narrative review highlights that while Phytolacca berry showed preliminary lipid-lowering effects in an animal model, there is currently no human clinical trial evidence to support its efficacy or safety in managing dyslipidemia, and it should not replace guideline-directed medical therapy such as statins.
Answers are grounded in this paper and cite their sources.
Do not recommend Phytolacca berry for dyslipidemia; leaves open efficacy pending human trials.
Dyslipidemia is a metabolic disorder characterized by abnormal levels of circulating lipids, including elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, or reduced high-density lipoprotein cholesterol (HDL-C). It is a major modifiable risk factor for atherosclerotic cardiovascular disease, including coronary artery disease and stroke. The increasing prevalence of obesity, sedentary lifestyles, unhealthy dietary habits, and metabolic disorders has made dyslipidemia an important public health concern. Early identification through lipid-profile assessment, lifestyle modification, and appropriate pharmacological treatment plays a significant role in reducing cardiovascular risk. Homoeopathy has traditionally emphasized individualized assessment, constitutional characteristics, and lifestyle-related factors. Phytolacca berry, associated with Phytolacca americana, has attracted research interest because of its proposed effects on lipid metabolism and body weight. A study by Hasan, Khan, and Kiran (2012) investigated Phytolacca preparations in hypercholesterolemia-induced rabbits and reported changes in lipid-profile parameters. However, this constitutes preliminary animal evidence and cannot establish clinical efficacy in humans. This review discusses the clinical features, risk factors, diagnosis, management, and available research concerning Phytolacca berry in dyslipidemia. Further well-designed human clinical trials are required to determine its efficacy and safety.
No takes yet. Share an insight, caveat, or question.
SUBHEDAR et al. (2026) conducted a review in Dyslipidemia. Phytolacca berry (Phytolacca americana) was evaluated on Lipid profile parameters (total cholesterol, triglycerides, LDL-C, HDL-C). Phytolacca berry has only preliminary animal evidence showing reductions in total cholesterol, triglycerides, and LDL-C, with insufficient human clinical trial data to establish efficacy or safety.
Synapse has enriched 10 related papers. Consider them for comparative context: